TNOX Tanox (MM)

HOUSTON, Sept. 19 /PRNewswire-FirstCall/ -- Tanox, Inc. (NASDAQ:TNOX) will deliver a presentation at the UBS Global Life Sciences Conference Sept. 26-29, 2005 in New York City. Tanox Vice President of Finance Greg Guidroz and Dr. Stanley Lewis, medical director, will present Sept. 29 at 8:30 a.m., EDT. Guidroz and Lewis will discuss upcoming corporate milestones and review the company's drug-development pipeline, including its most advanced investigational drug, TNX-355, for the treatment of HIV and AIDS. An audio webcast of the presentation will be accessible on the company Web site at http://www.tanox.com/ in the Investor Relations section. Presentation slides will be on the site following the webcast. About Tanox, Inc. Tanox is a biotechnology company specializing in the discovery and development of biotherapeutics based on monoclonal antibody technology. The company develops innovative therapeutic agents for the treatment of immune-mediated diseases, inflammation, infectious disease and cancer. Tanox's lead investigational therapy, TNX-355, is a humanized, anti-CD4 monoclonal antibody to treat HIV and AIDS. TNX-355 received Fast Track Status from the U.S. Food and Drug Administration in 2003 and is currently in Phase 2 clinical testing. Tanox's first-approved drug, Xolair(R) (omalizumab), is the first anti-immunoglobulin E (anti-IgE) antibody to be brought to market. Xolair was developed in collaboration with Genentech, Inc. and Novartis Pharma AG and was approved for marketing in the United States in 2003 for adult and adolescent patients with moderate-to-severe, confirmed allergic asthma. Tanox is based in Houston, Texas and maintains a manufacturing facility in San Diego, California. Additional corporate information is available at http://www.tanox.com/ . http://www.newscom.com/cgi-bin/prnh/20050207/TNOXLOGO DATASOURCE: Tanox, Inc. CONTACT: Steve Sievert of Tanox, Inc., +1-713-578-4211, or Web site: http://www.tanox.com/

Copyright